RespireRx Pharmaceuticals Inc. RSPI
0.00 USD 0.00 (+0.00%)
At closeDec 15, 2025, 4:00 PM EST
0.0014 Day range 0.0018
0.0001 52-week range 0.0027
- YTD
- 0.00%
- 1 year
- +125.00%
News
defenseworld.net Reviewing Cortex Pharmaceuticals (OTCMKTS:RSPI) & Stoke Therapeutics (NASDAQ:STOK) Cortex Pharmaceuticals (OTCMKTS:RSPI - Get Free Report) and Stoke Therapeutics (NASDAQ: STOK - Get Free Report) are both small-cap medical companies, but which is the better investment? We will…
globenewswire.com RespireRx Pharmaceuticals Inc. CFO and CEO Issue Letter to Stockholders, Stakeholders, Strategic and Potential Strategic Partners and Other Interested Parties Glen Rock, N.J., Nov. 20, 2025 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (RespireRx or the Company), and its subsidiaries, EndeavourRx LLC (EndeavourRx) and ResolutionRx Ltd (ResolutionRx),…
globenewswire.com RespireRx Pharmaceuticals Inc. Announces NIH/NINDS Grant Award and Amended and Restated Patent License Agreement Glen Rock, N.J., Nov. 19, 2025 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments…
globenewswire.com RespireRx Pharmaceuticals Inc. Announces a Department of Defense Award to Fund a Phase 2 Clinical Study to Determine the Safety and Efficacy of CX1739, its Lead AMPAkine, to Improve Bladder Function in Patients with Spinal Cord Injury Glen Rock, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Markets: RSPI) (RespireRx or the Company), focused on the discovery and development of innovative and…
globenewswire.com RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury Glen Rock, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) (“RespireRx” or the “Company”), focused on the discovery and development of innovative and…
proactiveinvestors.com RespireRx's key asset moves to next stage of NIH initiative RespireRx Pharmaceuticals (OTC:RSPI) Inc, a pioneer in the field of neuronal signaling treatments, said its lead compound, KRM-II-81, has progressed to the next evaluation phase of the National…
globenewswire.com RespireRx Pharmaceuticals Inc. Reports Preclinical Pain Relief for their Non-Opioid Lead GABAkine Glen Rock, N.J., Feb. 13, 2024 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and…
proactiveinvestors.com RespireRx Pharmaceuticals strengthens board, adding new director RespireRx Pharmaceuticals (OTC:RSPI) has strengthened its board, with the appointment of Dr Dariusz Nasiek as a director. The drug discovery firm focussed on psychiatric and neurological disorders,…
globenewswire.com RespireRx Pharmaceuticals Inc. Announces the Appointment of Dr. Dariusz Naziek to Its Board of Directors Glen Rock, N.J., Jan. 22, 2024 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and…
proactiveinvestors.com RespireRX Pharmaceuticals reports ‘highly encouraging' case study results for KRM-II-81 RespireRx Pharmaceuticals (OTC:RSPI) said a case study demonstrating positive results from the treatment of an epilepsy patient involving its therapeutic KRM-II-81 has been published in a…
globenewswire.com RespireRx Pharmaceuticals Inc. Announces the Publication of a Case Report in which KRM-II-81 Totally Suppressed Epileptiform Activity in Brain Tissue Surgically Removed from Epileptic Patient Glen Rock, N.J., Jan. 04, 2024 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and…
proactiveinvestors.com RespireRX Pharmaceuticals announces Ponto Ventures' MD Will Clodfelter will help drive business development RespireRx Pharmaceuticals (OTC:RSPI) has announced an agreement with Ponto Ventures LLC under which Will Clodfelter will serve as its senior vice president of business development on a part-time…
globenewswire.com RespireRx Pharmaceuticals Inc. Announces Agreement with Ponto Ventures to Drive Business Development with Will Clodfelter as RespireRx Part-Time Senior VP of Business Development Glen Rock, N.J., Dec. 11, 2023 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) (“RespireRx” or the “Company”), a biopharmaceutical company focused on the discovery and…
proactiveinvestors.com RespireRx Pharmaceuticals subsidiary inks MSA for dronabinol manufacturing RespireRx Pharmaceuticals (OTC:RSPI) Ltd and its ResolutionRx subsidiary announced that it has entered into a Master Services Agreement (MSA) with Australia's Ab Initio Pharma Pty Ltd (Ab Initio),…
globenewswire.com RespireRx Pharmaceuticals Inc.'s Subsidiary ResolutionRx Ltd Enters into Master Services Agreement for Dronabinol Manufacturing and Related Services Glen Rock, N.J., Oct. 12, 2023 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) (“RespireRx” or the “Company”), focused on the discovery and development of innovative and…
proactiveinvestors.com RespireRx to transfer cannabinoid research program to Australian subsidiary ResolutionRx RespireRx Pharmaceuticals (OTC:RSPI) shares rose on Wednesday morning after it announced that it has entered into agreements with its Australian subsidiary ResolutionRx to transfer RespireRx's…
globenewswire.com RespireRx Pharmaceuticals Inc. and ResolutionRx Ltd Enter into Bilateral Agreements to Establish ResolutionRx Ltd as an Operating Company Glen Rock, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC. Pink Market: RSPI) (“RespireRx”), focused on the discovery and development of innovative and revolutionary…
proactiveinvestors.com RespireRx Pharmaceuticals' Australia cannabis subsidiary inks LOI securing $3.1M investment RespireRx Pharmaceuticals (OTC:RSPI) Inc subsidiary ResolutionRx Ltd entered into a binding letter of intent last week with Cantheon Capital, in which the latter would help fund the former's clinical…
proactiveinvestors.com RespireRx Pharmaceuticals highlights analogs of its anti-seizure treatment in scientific publications RespireRx Pharmaceuticals (OTC:RSPI) Inc has announced the publication of four articles describing the pharmacological activity of novel structural analogs of KRM-II-81, the company's lead…
proactiveinvestors.com RespireRx Pharmaceuticals appoints Joseph Siegelbaum as independent director on its board RespireRx Pharmaceuticals (OTC:RSPI) Ltd has announced the appointment of Joseph Siegelbaum to the company's board as an independent director, effective March 22, 2023. The biopharma firm said…
benzinga.com Stocks That Hit 52-Week Lows On Tuesday 
benzinga.com Stocks That Hit 52-Week Lows On Friday 
benzinga.com Stocks That Hit 52-Week Lows On Friday